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Since the discovery of prion diseases, the concept has emerged that a protein could be
a transmissible pathogen. As such, this transmissible pathogen agent can transfer its
pathological mis-folded shape to the same but normally folded protein thus leading to
the propagation of a disease. This idea is now extrapolated to several neurological dis-
eases associated with protein mis-folding and aggregation, such as Alzheimer’s disease
(AD). AD is a slowly developing dementing disease characterized by the coexistence of
two types of lesions: the parenchymal amyloid deposits and the intraneuronal neurofibril-
lary tangles (NFT). Amyloid deposits are composed of amyloid-beta peptides that derive
from sequential cleavages of its precursor named amyloid protein precursor. NFT are char-
acterized by intraneuronal aggregation of abnormally modified microtubule-associated Tau
proteins. A synergistic relationship between the two lesions may trigger the progression
of the disease. Thus, starting in the medial temporal lobe and slowly progressing through
temporal, frontal, parietal, and occipital cortex, the spreading of NFT is well correlated
with clinical expression of the disease and likely follows cortico-cortical neuronal circuitry.
However, little is known about the mechanism driving the spatiotemporal propagation of
these lesions ultimately leading to the disease. A growing number of studies suggest that
amyloid deposits and NFT are resulting from a prion-like spreading. In the present chapter,
we will develop the current hypotheses regarding the molecular and cellular mechanisms
driving the development and spreading of AD lesions from the window of multivesicular
endosomes/bodies and exosomes.
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ALZHEIMER’S DISEASE, AMYLOID DEPOSITS, AND APP
METABOLISM
Alzheimer’s disease (AD) is a slow and progressive disease affect-
ing the brain and characterized by the loss of superior cognitive
functions ultimately leading to dementia and death. Two neu-
ropathological brain lesions are found in the brain and their
presence is necessary for providing a definite diagnosis of the
disease, as firstly described by Alzheimer (1911).
Amyloid deposits are amorphous parenchymal deposits of β-
sheet ordered proteinaceous material. They are observed with
aging, in AD, Down’s syndrome, dementia with Lewy bodies, and
vascular dementia, all of which are aged-related neurodegener-
ative disorders. The major component of amyloid deposits is a
small peptide of 39 to 43 amino acid residues, named Aβ for
amyloid-beta peptide (Glenner and Wong, 1984). It derives from
a sequence of successive cleavages of a larger precursor protein
named APP. APP gene is located on the long arm of chromo-
some 21 at position 21q11.2 (Goldgaber et al., 1987; Kang et al.,
1987). APP is a type I transmembrane protein with a large extra
amino-terminal membrane domain, a transmembrane domain,
and a short carboxy-terminal cytosolic tail composed of 59 amino
acids (Figure 1). The principal role of APP remains elusive but
several functions are proposed, for instance APP was recently sug-
gested to contribute to iron cellular homeostasis (Duce et al.,2010),
to regulate intracellular transport via its interaction with motor
proteins such as kinesin, to be a cell surface receptor. Extracellu-
lar fragments derived from the cleavage of APP were suggested to
be neuroprotective or to promote axon outgrowth (Chasseigneaux
et al., 2011) whereas others functions are associated to an ancestral
immunological mechanism of defense and would potentially have
antibacterial peptide property (Soscia et al., 2011). However, the
full spectrum of APP isoform functions remains to be elucidated.
Proteolytic cleavage of APP brings into play sequential events
involving first the release of its ectodomain either by α- or β-
secretase activities (Figure 1). These cleavages generate carboxy-
terminal fragments remaining anchored to the plasma membrane
and they shed extracellular soluble fragments, both of which are
playing a role in axon outgrowth in vitro (Chasseigneaux et al.,
2011). APP cleavage by α-secretase generates a soluble APP frag-
ment α (sAPPα) and a carboxy-terminal α fragment composed
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FIGURE 1 | Amyloid protein precursor structure and metabolism.
Schematic representation of APP processing by α-, β-, and γ-secretases. APP
processing by secretase activities is divided into the non-amyloidogenic
pathway on the left and the amyloidogenic pathway on the right. α- and
β-secretase activities cleave APP in its extracellular domain to release
respectively a soluble fragment sAPPα or sAPPβ in the extracellular space and
generate carboxy-terminal fragments CTFα or CTFβ. These CTFs can
subsequently be processed by γ-secretase complex to generate AICD and
Aβ. The γ-secretase complex is composed of presenilin, nicastrin (NCT),
γ-secretase activating protein (GSAP), pen-2, and aph-1.
of 83 amino acids (named C83 or CTFα; for review see Vingt-
deux and Marambaud, 2012). This cleavage takes place within the
sequence of Aβ peptide thus precluding its formation. This path-
way is therefore referred to as the non-amyloidogenic pathway.
Theα-secretase activity is carried by metalloproteases called A Dis-
integrin And Metalloprotease (ADAMs). Several ADAM proteases
with anα-secretase activity have been identified, including ADAM-
17 or TNF-α converting enzyme (TACE; EC 3.4.24.86, peptidase
family M12; Buxbaum et al., 1998), ADAM-10 (EC 3.4.24.81, pep-
tidase family M12; (Lammich et al., 1999; Lopez-Perez et al., 2001),
and ADAM-9 (EC 3.4.24.; Koike et al., 1999; Hotoda et al., 2002).
The β-secretase cleaves APP at the first amino acid residue of Aβ
sequence. The β-cleavage generates a soluble fragment sAPPβ and
a CTF comprised of 99 amino acids (C99 or CTFβ). All APP-CTFs
(CTFα, β′, and β) can subsequently be cleaved at the juxtamem-
brane region by the γ-secretase (Figure 1). However, ectodomain
cleavage of APP is mandatory to intramembraneγ-secretase prote-
olysis of APP-CTFs. The APP intracellular domain (AICD or C51)
is released from both CTFα and CTFβ by the γ-secretase following
the cleavage at the ε-site. However, CTFs can also be processed at
the γ-sites but yet AICD of 57 or 59 amino acids have not been
detected (for review see Pardossi-Piquard and Checler, 2011). The
γ-secretase cleavage of CTFβ represents the last step of Aβ pro-
duction and is currently considered to be the pathway releasing
AICD in the cytoplasm, thus having a potential gene regulatory
function together with Fe65 and Tip60 (Konietzko et al., 2010).
Following cleavages sites are the γ-sites which produce Aβ species
of 43, 42, 40, 39, 38, 37 amino acid long following the rule of tri-
or tetrapeptide release (Takami et al., 2009; for review see Karran
et al., 2011). The γ-secretase is a multiprotein complex composed
of at least four proteins, Presenilin, Pen-2, Aph-1, Nicastrin, and
one molecule of each is necessary and sufficient to form an active
enzymatic complex (Edbauer et al., 2003; Kimberly et al., 2003;
Takasugi et al., 2003; Sato et al., 2007).
Theα- and β-secretases are sheddases releasing the extracellular
domain of APP as well as several others type I transmembrane pro-
teins. The cleavage and localization of enzyme activity is supposed
to occur at the plasma membrane or in early endosomes. As for
instance, BACE-1 resides within endosomes and APP endocytosis
is a prerequisite for cleavage of APP by BACE-1 and generation
of Aβ (Vassar et al., 1999; Walter et al., 2001; Ehehalt et al., 2003).
BACE-1 optimal protease activity necessitates an acidic pH and
acidification of endosome occurs during the route of endosomes
to fuse with lysosomes where BACE-1 is degraded (Koh et al.,
2005). Cleavage of APP-CTFs by γ-secretase can occur at sev-
eral places in the cell (e.g., plasma membrane, endosomes. . .).
Discrepancies exist regarding the cell localization of γ-secretase
by-products. Several APP metabolites including APP, APP-CTFs,
Aβ, and AICD have been shown to accumulate in multivesicu-
lar bodies (MVBs) following treatment of cells with alkalizing
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drugs (Verbeek et al., 2002; Vingtdeux et al., 2007b). Interest-
ingly and similarly to the effect of Gleevec, alkalizing drugs such
as chloroquine, ammonium chloride, bafilomycin A1, block Aβ
production without affecting AICD generation (Vingtdeux et al.,
2007a). More interestingly, following treatment, the AICD amount
raise and AICD is also released outside the cell. Inside the cell AICD
is reaching the nucleus (Goodger et al., 2009) where it regulates
gene expression such as neprelysin (Pardossi-Piquard et al., 2005;
for review see Pardossi-Piquard and Checler, 2011). Interestingly,
intracellular AICD may be generated from APP-CTFs produced
from β-secretase (Belyaev et al., 2010). However, further investiga-
tion is needed to determine whether there is one or several AICD
and what is the function of AICD. For instance, BACE-1 cleavage
of APP and AICD derived from βCTF may contribute to learning,
memory, and neuronal plasticity (Ma et al., 2007).
ALZHEIMER’S DISEASE, NEUROFIBRILLARY TANGLES, AND
MICROTUBULE-ASSOCIATED TAU
Neurofibrillary tangles are characterized by intraneuronal accu-
mulation of fibrillar material named paired helical filaments (Kurt
et al., 1997). Abnormally modified Tau proteins are the major com-
ponents of this filamentous material. Tau proteins belong to the
family of microtubule-associated proteins. A single gene, named
MAPT located at position 17q21 encoded for several isoforms
resulting from alternative splicing of exons 2, 3, and 10 in the
human adult brain. There are six isoforms, half of which con-
tains the exon 10 encoding sequence, two-third are having the
exon 2 whereas the exon 3 is found in one-third of Tau iso-
forms and always in association with exon 2. The Tau isoforms
differ from each other by the presence of either three (3R) or four
repeat-regions (4R) in the carboxy-terminal (C-terminal) part of
the molecule and the absence or presence of one or two inserts
(29 or 58 amino acids) in the amino-terminal (N-terminal) part
(Goedert et al., 1989a,b; Andreadis et al., 1992). Each of these iso-
forms is likely to have particular physiological roles since they are
differentially expressed during development. For instance, only
one Tau isoform, characterized by 3R and no N-terminal inserts,
is present during fetal stages, while the six isoforms (with one
or two N-terminal inserts and 3 or 4R) are expressed during
adulthood (Kosik et al., 1989; Goedert and Jakes, 1990). Tau iso-
forms are differentially distributed in neuronal subpopulations or
in yet underdetermined physiological conditions (Goedert et al.,
1989a). However, in pathological conditions such as frontotempo-
ral dementia linked to chromosome 17 or myotonic dystrophy, a
mis-splicing of Tau is associated to the development of neurofib-
rillary degeneration (Vermersch et al., 1996; Hutton et al., 1998;
Spillantini et al., 1998; Sergeant et al., 2001).
Tau proteins bind microtubules through repetitive regions in
their C-terminal part. These repetitive regions are the repeat
domains (R1–R4) encoded by exons 9 to 12 (Lee et al., 1989).
The three (3R) or four copies (4R) are made of a highly con-
served 18-amino acid repeat ending with a PGGG motif (Lee
et al., 1988; Goedert et al., 1989b, Himmler et al., 1989; Lee et al.,
1989) and separated from each other by less conserved 13- or 14-
amino acid inter-repeat domains. Tau proteins are known to act
as promoter of tubulin polymerization in vitro, and are involved
in axonal transport (Weingarten et al., 1975; Cleveland et al.,
1977; Brandt and Lee, 1993). Adult Tau isoforms with 4R (R1–
R4) are more efficient at promoting microtubule assembly than
the fetal isoform with 3R (R1, R3–R4; Goedert and Jakes, 1990;
Butner and Kirschner, 1991; Gustke et al., 1994). Besides its major
microtubule-binding, -stabilizing, paralleled-ordering functions,
Tau also has other functions.
Tau proteins bind to spectrin and actin filaments (Selden and
Pollard, 1983; Carlier et al., 1984; Correas et al., 1990; Hen-
riquez et al., 1995). Through these interactions, Tau proteins may
allow microtubules to interconnect with other cytoskeletal com-
ponents such as neurofilaments (Miyata et al., 1986; Andreadis
et al., 1995) and may restrict the flexibility of the microtubules
(Matus, 1990). There is also evidence that Tau proteins interact
with cytoplasmic organelles. Such interactions may allow for bind-
ing between microtubules and mitochondria (Jung et al., 1993).
The Tau N-terminal projection domain also permits interactions
with neural plasma membrane (Brandt et al., 1995). Thus, Tau
may act as a mediator between microtubules and plasma mem-
brane. This interaction has been defined as involving a binding
between the proline-rich sequence in the N-terminal part of Tau
proteins and the SH3 domains of Src-family non-receptor tyro-
sine kinases, such as Fyn. Studies have determined that human
Tau Tyr18 and Tyr29 are phosphorylated by the Src-family tyro-
sine kinase Fyn (Williamson et al., 2002; Lee et al., 2004). Tau
proteins was shown to co-sediment with lipid-raft fractions in
response to Aβ and corresponded to phosphorylated Tau pro-
teins at Tyr18 and Ser396/404 (Hernandez et al., 2009). In this
latter study, it is suggested that Tau association to lipid-rafts may
be necessary to mediate Aβ toxicity through the stabilization of
Tau/Cdk5 interaction and thus suggesting that Tau as a poten-
tial signal transduction protein. The proline-rich region of Tau
proteins is likely involved in the interaction with phospholipase
C-γ (PLC-γ) isozymes (Hwang et al., 1996; Jenkins and John-
son, 1998). Hwang and colleagues have demonstrated in vitro that
Tau proteins complex specifically with the SH3 domain of PLC-
γ, and enhance its activity in the presence of unsaturated fatty
acids such as arachidonic acid. These results suggest that in cells
that express Tau proteins, receptors coupled to cytosolic phos-
pholipase A2 may activate PLC-γ indirectly, in the absence of the
usual tyrosine phosphorylation, through the hydrolysis of phos-
phatidylcholine to generate arachidonic acid (Hwang et al., 1996;
Jenkins and Johnson, 1998). Altogether, these data indicate that
Tau proteins may also play a role in the signal transduction path-
way involving PLC-γ (for review see Rhee, 2001). In line with this
idea, recent data demonstrate that Tau is necessary for glutamater-
gic signaling (Ittner et al., 2010). Overall, there is a growing body
of evidence suggesting that tau may be close, interact, or even
associate with intracellular vesicular compartment.
THE SPATIOTEMPORAL BRAIN SPREADING OF
NEUROFIBRILLARY DEGENERATION
With aging, neurofibrillary tangles (NFT) spread from the transen-
torhinal cortex to the hippocampal formation. Neuropathological
as well as biochemical assessment show that the Tau pathology
spreads progressively, invariably, hierarchically, from the transen-
torhinal cortex to the whole neocortex, along cortico-cortical con-
nections. The brain regions that are sequentially affected explain
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well the successive kind of cognitive impairments that characterize
the disease: amnesia following the entorhinal and hippocampal
degeneration: aphasia, apraxia, and agnosia with the involve-
ment of the neocortex. Of course, amyloid and Tau pathology
are present far early before the clinical symptoms (for review see
Karran et al., 2011), because neuronal plasticity likely compen-
sate at the first AD stages. Recently, the locus coeruleus has been
described as the initiating region of NFD (Braak and Del Tredici,
2011). The Tau pathology is already distributed in the hippocam-
pal formation and the temporal cortex at the “pre-clinical” stage
of AD (Delacourte et al., 1999, 2002). Tau pathology, visualized
as a triplet of abnormal Tau proteins, is systematically present in
variable amounts in the entorhinal and hippocampal regions of
non-demented patients aged over 75 years. When Tau pathology is
found in other brain areas, it is always along a stereotyped, sequen-
tial pathway categorized into 10 stages according to the brain
regions successively affected: transentorhinal cortex (S1), entorhi-
nal (S2), hippocampus (S3), anterior temporal cortex (S4), inferior
temporal cortex (S5), mid temporal cortex (S6), polymodal asso-
ciation areas (prefrontal, parietal inferior, temporal superior; S7),
unimodal areas (S8), primary motor (S9a) or sensory (S9b, S9c)
areas, and all neocortical areas (S10). Up to stage 6, the disease
could be asymptomatic. In all of the cases at stage 7, individuals
with two polymodal association areas affected by Tau pathology
are cognitively impaired. This is of importance since it suggests
that the spreading process occurs far before the occurrence of
clinical symptoms and is also a very slow process likely transmit-
ted through cortico-cortical connections therefore following rules
and not randomly and most likely not diffusely. This hypothe-
sis has been recently supported by different experimental works
(Clavaguera et al., 2009, 2010; De Calignon et al., 2012; Liu et al.,
2012). In contrast, amyloid deposits are diffusely progressing in
the brain parenchyma (Braak and Braak, 1991; Duyckaerts and
Hauw, 1997). However the mechanisms underlying the spreading
and propagation of lesions remains poorly understood and cur-
rent hypothesis, supported by the most recently published studies,
suggested the spreading of AD lesions through interconnected
neuronal circuitries. Among several hypotheses, we suggest that
exosomes may contribute to this spreading process. Exosomes are
produced from multivesicular endosomes and they will be first
described followed by exosomes and the potential mechanism for
the selectivity of spreading.
MULTIVESICULAR ENDOSOMES AND EXOSOMES
Extracellular components, such as viruses, ligands, or diffusible
factors and, part of the plasma membrane proteins are inter-
nalized during endocytosis. They are either recycled to the cell
surface via early or recycling endosomes or, they are directed to
late endosomes and finally delivered to lysosomes for degrada-
tion (for review see Gruenberg, 2009). Late endosomes are also
known as multivesicular endosomes or MVBs (Gruenberg and
Stenmark, 2004; Raposo and Marks, 2007; Rusten et al., 2011).
They are required for the degradation of internalized material to
fuse with lysosomes and are instrumental to several cellular func-
tions including miRNA activity, mRNA transport, autophagy, cell
polarity, receptor signaling, cytokinesis, and migration (Huotari
and Helenius, 2011; Rusten et al., 2011). MVBs are large vesicles of
several hundred nanometers that are characterized by numerous
smaller intraluminal vesicles (ILVs) formed by the inward bud-
ding of the endosome limiting membrane. The formation of these
ILVs requires sequential steps and the contribution of complex of
multi-molecular machinery named Endosomal Sorting Complex
Required for Transport (ESCRT). The ESCRT machinery is com-
posed of four ESCRT protein complexes (0, I, II, and III) acting
sequentially to sort ubiquitinated cargo and to form a coated sub-
domain on endosomes that forms the ILVs (Figure 2). Evidences
for alternative pathways for cargos sorting into MVBs are emerg-
ing, which are independent of the ESCRT machinery but seems
to depend on the lipid composition of raft-based micro domains.
Proper cholesterol levels in late endosomes are required for normal
MVBs formation and MVB-mediated membrane protein degrada-
tion (Kobuna et al., 2010). It was also shown that the phospholipid
LBPA (lysobisphosphatidic acid) and ceramide possess the capac-
ity to drive the formation of membrane invaginations (Matsuo
et al., 2004; Trajkovic et al., 2008). Ubiquitination (Ub) is the main
sorting signal for cargo entry into the vesicles that bud from the
limiting membrane into the lumen of endosomes during the bio-
genesis of MVBs. A single Ub is sufficient to direct ILV targeting.
Ub is recognized by an expanding cohort of endosomal proteins,
which may act as Ub-sorting receptors responsible for binding and
directing cargo toward ILVs like some ESCRT subunits, includ-
ing VPS27/Hrs, VPS23/Tsg101, and VPS36/Eap45 (for review see:
Piper and Katzmann, 2007). Many integral membrane proteins
targeted for lysosomal degradation are ubiquitinated; however,
non-ubiquitin sorting signals have also been described. Much less
is known about non-Ub signals that sort proteins to ILVs; proteins
which have been described to enter ILVs in an Ub-independent
manner include Pmel17/Silver (Berson et al., 2003), TfR (Gem-
inard et al., 2004), Nedd4 (Morita and Sundquist, 2004), Sna3
(McNatt et al., 2007; Oestreich et al., 2007). Two motifs “NTR” and
“PKD” located on the extracellular part of Pmel17 are responsible
for its targeting into the internal vesicles of MVBs (Theos et al.,
2006) and COP9 signalosome (CSN)-associated protein Csn5 is
involved in protein sorting into ILVs since siRNA of Csn5 causes a
significant increase in both ubiquitinated and non-ubiquitinated
proteins detected in exosomes (Liu et al., 2009).
Genetics also supports the importance of functional MVB
in neurological disease and frontotemporal dementia. The gene
encoding CHMP2B the ESCRT-III subunit was found to be
mutated in a form of frontotemporal dementia (Skibinski et al.,
2005) and amyotrophic lateral sclerosis (Cox et al., 2010) suggest-
ing that functional MVBs are required to prevent accumulation of
abnormal proteins that can disrupt neural function and ultimately
lead to neurodegeneration (Filimonenko et al., 2007). Mutations
in CHMP2B were first described in Danish and Belgian families
but remain rare (Ghanim et al., 2010), yet accounting for less
than 1% of Frontotemporal lobar degeneration linked to chro-
mosome 3 (FTD-3; Isaacs et al., 2011; Gijselinck et al., 2012).
Mutations CHMP2BIntron5 or CHMP2BDelta10 are supposed to
lead to C-terminal truncation of CHMP2B. Brain tissue exam-
ination of patients with CHMP2B mutation showed enlarged
vacuoles stained with a mannose-6-phosphate receptor antibody.
The truncated protein impairs the fusion of endosome with lyso-
somes without obvious modification of protein sorting to MVB
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FIGURE 2 |The microtubule-associated protein tau.The six human brain
isoforms of tau are represented. They differ by the inclusion of exclusion of
exons 2 (yellow), exon 3 (orange), and exon 10 (light blue). The
microtubule-associated domain are indicated in blue and depending on
inclusion of exon 10 there are tau isoforms with 4 (4R) or 3 (3R)
microtubule-binding regions. The fetal isoform is lacking the alternative
encoding cassettes 2, 3, and 10. Tau protein binds the microtubule lattice
through its microtubule-binding domains shown in blue.
(Urwin et al., 2010). Ectopic expression of mutant CHMP2BIntron5
in primary cortical rodent neurons promote neuronal cell death
through the failure of the mutant protein to dissociate from
ESCRT-III complex. In parallel, an increased accumulation of
autophagosomes was observed suggesting a defective fusion of
autophagosomes with MVB (Lee et al., 2007). Staining of tis-
sue from Alzheimer disease patients with CHMP2B showed an
accumulation of the protein in vesicular structures resembling
Granulo Vacuolar Degeneration (Yamazaki et al., 2010; Funk
et al., 2011) suggestive of a defective autophagic and late endo-
cytic pathways in AD and Frontotemporal lobar degeneration.
MVB function is required for the proper clearance of intra-
cellular protein aggregates such as TDP-43 or polyglutamine
aggregates observed in Frontotemporal lobar degeneration and
amyotrophic lateral sclerosis or Huntington disease, respectively
(Filimonenko et al., 2007). Moreover, restoring or enhancing the
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lysosomal degradation and rates of autophagic protein turnover
in a transgenic animal model of amyloid deposition can rescue the
phenotype and decrease the amyloid burden (Yang et al., 2011).
Together, a defective function of the endocytic pathway including
MVB, autophagy, and lysosome may certainly contribute to the
development of several neurodegenerative diseases including AD.
Alternatively to their fusion with lysosomes for degradation of
their contents, MVBs have been described to fuse to the plasma
membrane and release their content in the extracellular space
(Harding et al., 1983; Pan et al., 1985), the ILVs contained in the
MVBs when released are referred to as exosomes (Johnstone et al.,
1987). Exosomes have a size ranging from 40 to 100 nm and can be
secreted by many cell types including neuronal cells (Faure et al.,
2006; Rajendran et al., 2006; Vingtdeux et al., 2007b; Lachenal
et al., 2011). Exosomes are isolated from the media of cultured
cells. However, purification of exosomes is not trivial since mem-
brane fragments or cell debris can easily contaminate exosome
preparations. Due to their small size, exosomes are obtained after
filtration on 0.22µm filters and by a series of centrifugation and
sucrose gradient (Raposo et al., 1996; Wubbolts et al., 2003; Faure
et al., 2006; Thery et al., 2006 for review see Olver and Vidal,
2007). Further immunoisolation can be used (Wubbolts et al.,
2003). Several parameters should be evaluated to ascertain the
purity of exosomes preparation. The first and likely most impor-
tant characteristic is the observation of exosomes by transmission
electron microscopy. Thus, exosomes have a typical cup-shape
form. Several proteins are also common to exosomes and described
in exosomes preparation that originate from different sources
(for review Vella et al., 2008). Interestingly, several tetraspanins
proteins are enriched in exosomes and may contribute to exo-
somes formation (Wubbolts et al., 2003; De Gassart et al., 2004).
Tetraspanins are a growing family of transmembrane proteins
with pleiotropic functions found associated with lipid-raft micro
domains (for review Hemler, 2005). Interestingly, tetraspanins
CD81 and CD9, which are found in exosomes derived from B-cells
(Wubbolts et al., 2003), are co-purified with the γ-secretase inter-
actome. Absence of those tetraspanins induces a partial disruption
of γ-secretase activity or reduces γ-secretase substrate interaction
(Wakabayashi et al., 2009). Although detailed molecular mecha-
nisms remain unknown, together those results further support the
idea that MVB and most possibly exosomes are important cellu-
lar compartments for APP metabolism regulation and that several
γ-secretase regulators may act at this level.
MVBs fate can be affected by macroautophagy (hereafter
referred to as autophagy). During autophagy, parts of the cyto-
plasm and organelles are encapsulated in double-membrane vac-
uoles called autophagosomes, which eventually fuse with lyso-
somes for degradation (for review see Levine et al., 2011).
Under conditions that stimulate autophagy, MVBs are diverted
to autophagic pathway with subsequent inhibition in exosomes
secretion (Fader et al., 2008). Conversely, knockdown expres-
sion of ESCRT-I, -II, and -III proteins in cell models promotes
the accumulation of autophagosomes or autolysosomes, suggest-
ing that MVB and autophagy are intermingled and that loss of
MVB function may promote autophagy as well as ineffective
fusion of autophagosomes and lysosomes (for review see Rusten
et al., 2011). Thus, loss of function of CHMP2B may impair both
MVB and autophagosome maturation. With regards to Tau, the
autophagy-lysosomal pathway contributes to the degradation of
Tau (Wang et al., 2011). However, Tau protein inclusions are sel-
dom detected in FTD-3 (Yancopoulou et al., 2003) and ubiquitin-
positive inclusions are observed but TDP-43 negative (Holm et al.,
2007).
How exosomes are processed in recipient cells is not yet fully
understood. Exosomes can be endocytosed into the endosomal
system of recipient cells. Once internalized, exosomes could fuse
with the limiting membrane of endosomes to deliver their cyto-
plasmic content into the host cell cytoplasm. It is also possible
that exosomes could directly fuse with the plasma membrane.
Although their exact function remains to be discovered, within
the extracellular space and in biological fluids such as urine or
serum, exosomes have been proposed to participate in different
physiological and/or pathological processes such as neurodegen-
erative diseases (for review see Vella et al., 2008). They could be
responsible not only for protein and lipids exchange between cells,
but also for mRNA and microRNAs exchange (Valadi et al., 2007).
Recently, miRNAs content of purified exosomes produced by den-
dritic cells were shown to ectopically repress target mRNAs of
recipient dendritic cells (Montecalvo et al., 2011). Exosome release
and content may be regulated by cellular stress. Thus DNA dam-
age and activation of p53 induce the expression of protein that
will be included inside exosomes (Yu et al., 2006). Exosomes may
mediate a signal of cellular damage or stress. In the central nervous
system, exosomes are proposed to constitute an intercellular com-
munication system (for review see Mathivanan et al., 2011, 2012).
Exosomes produced by glia-derived cells stimulate neurite out-
growth through a synapsin and NCAM dependent mechanism. In
oxidative stress condition the synapsin released from exosomes
is neuroprotective (Wang et al., 2011). AICD and several APP
metabolites are found in exosomes derived from primary neu-
ronal cultured cells (Vingtdeux et al., 2007b; Figure 3). L1 CAM
that is also processed by γ-secretase (Riedle et al., 2009) is recov-
ered in exosomes (Lachenal et al., 2011). Interestingly, modulators
of the γ-secretase activity, such as inhibitors, modulate the release
of APP-CTFs and Aβ associated to exosomes (Sharples et al.,
2008). Altogether, there is a growing body of evidence suggest-
ing that exosomes are small membrane-delineated cell-secreted
material that may participate in cell-to-cell communication via
both RNAs and proteins. Although speculative, if several intracel-
lular domains of proteins processed by γ-secretase are internalized
and secreted within exosomes, the fusion of those exosomes with
surrounding cells may regulate gene expression by those intracellu-
lar domains and therefore constitute another cell communication
system. However, if proteins that are degraded through late endo-
somes/lysosomes pathway are diverted from this normal degrading
route, it may promote their accumulation, shape-transformation,
and secretion via the multivesicular and exosome pathway.
PRION-LIKE PROPAGATION OF AMYLOID AND TAU
PATHOLOGIES
Besides being a potential system of intercellular communication,
exosomes are also known to be instrumental to the dissemina-
tion of pathogens, whether those are viruses or proteinaceous
pathogens. The first pathological protein described associated with
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FIGURE 3 | Model for the ubiquitin-dependent sorting of proteins by
the ESCRT machinery.The ESCRT machinery is composed of four
ESCRT protein complexes (0, I, II, and III) acting sequentially to sort
ubiquitinated (ubiquitin is represented as Ub) cargo and to form a coated
subdomain on endosomes that forms the ILVs. The VPS27/
Hrs-Hse1/STAM complex (ESCRT-0) is first recruited to the endosomes
by binding PI(3)P and ubiquitinated cargos. ESCRT-0 then recruits
ESCRT-I (composed of Tsg101/VPS23-VPS28-VPS37) to the membrane,
where ESCRT-I interacts with ubiquitinated cargos via its VPS23 subunit.
Then, ESCRT-I recruits ESCRT-II complex (composed of
VPS22/Eap30-VPS25/Eap25-VPS36/Eap45), which in turn initiates the
oligomerization of ESCRT-III complex (composed of
VPS2/CHMP2-VPS20/CHMP6-VPS24/CHMP3-Snf7/VPS32/CHMP4).
ESCRT-I and II initiate the invagination of the limiting endosomal
membrane. ESCRT-III deubiquitinating enzymes ensure the dissociation
of ubiquitin residues from molecules before sequestration into MVBs.
Finally, ESCRT-III recruits supplementary factors like Bro1 and Vsp4
AAA-ATPase. Bro1 will recruit a deubiquitination enzyme whereas VPS4
AAA-ATPase will work to break apart ESCRT-III and other ESCRT
complexes, resulting in their dissociation from the membrane.
exosomes was the prion protein (PrP; Fevrier et al., 2004; Alais
et al., 2008). Prions diseases are fatal neurodegenerative disor-
ders. They are associated with the conversion of the cellular prion
protein (PrPc) into the scrapie PrP (PrPSc), an abnormal confor-
mational state that tends to form amyloid deposits in brain tissue
leading to dementia. Into its mis-folded conformation the PrPSc
is thought to be infectious (for review see Aguzzi and Rajendran,
2009). Recent findings revealed an unexpected role for exosomes in
dissemination of prions: exosomes from prion-infected neuronal
cells have been demonstrated to be efficient initiators of prion
propagation in uninfected recipient cells and, more importantly,
to produce prion disease when inoculated into mice (Vella et al.,
2007).
PRION-LIKE PROPAGATION OF AMYLOID PATHOLOGY
Exosomal release instead of lysosomal processing might be of
advantage to cells having poor degradative capacities. In the con-
text of AD, exosomes secretion could be a way to dispose of
unwanted proteins. Indeed, maturation of autophagolysosomes
and their retrograde transport are most possibly impeded in
AD (Lee et al., 2011). The underlying mechanism behind the
hypothesis that neurodegeneration in AD is triggered by protein
spread, cell-to-cell, throughout brain areas could be the shipping
of toxic agents such as Aβ or Tau by exosomes. What at the begin-
ning would be beneficial (to bypass a degradation system which
is overwhelmed) could become the reason why there is propaga-
tion of the disease thorough the brain. Aβ peptides are released
by cells in association with exosomes (Rajendran et al., 2006) and
interestingly, exosomal proteins such as Alix and flotillin-1 were
observed around neuritic plaques, a lesion found in brains from
AD patients (Rajendran et al., 2006) suggesting that exosomes-
associated Aβ could be involved in plaque formation. MVBs are
an intracellular compartment where internalized Aβ can grow into
fibrils thereby MVBs may also contribute to amyloid plaque for-
mation (Friedrich et al., 2010). Overall these results suggest that
exosomes could play a role in the pathogenesis of AD. The idea of a
“prion-like” propagation of Aβ lesions is also supported by results
obtained in vivo in human wild-type APP transgenic mice (HuAP-
Pwt) which do not develop Aβ deposits. Intracerebral inoculations
of AD brain homogenates into the hippocampus of these mice lead
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to Aβ deposits which increased with age and spread to areas other
than the site of injection (Morales et al., 2011). Propagation of Aβ-
induced molecular impairments across synapses is also suggested
in a transgenic animal model in which the expression of APP was
restricted to the entorhinal cortex. With time and aging, amyloid
deposits were observed in connected brain regions such as the
dentate gyrus and CA1 pyramidal neurons (Harris et al., 2010).
Entorhinal cortex neurons are neither directly connected to the
granular cells of the dentate gyrus nor to CA1 pyramidal neurons.
Therefore, amyloid deposits that appear with aging in those struc-
tures may originate from pathological Aβ species that propagate
across synapses. A possible hypothesis would be that the patho-
logical Aβ species are produced and released through the exosome
pathway and exosomes are caught by interconnected neurons and
trans-synaptically delivered to connected brain regions.
TAU PATHOLOGY SPREADING
The stereotype propagation scheme of neurofibrillary degener-
ation in AD is evidenced by neuropathological examination as
well as biochemical analyses but until recently, hypotheses and
experiments trying to address this question remained elusive. Neu-
rofibrillary degeneration is following stereotypical brain circuitry
following cortico-cortical connections therefore suggesting a loss
of neurotrophic or surviving factor or a diffusible factor respon-
sible for a cascade of molecular events leading to Tau aggregation
and neuronal death. However, what is this propagating factor?
What if Tau itself wouldn’t be the “missing link”? Thus, recent data
suggest that neurofibrillary degeneration cortical spreading could
follow a transmissible prion-like process. In fact, aggregates of
PHF-Tau were purified from a transgenic mice model of neurofib-
rillary degeneration. Intracranial injection of this preparation was
done in a different mouse model, which overexpresses human Tau
protein but does not display Tau pathology. Following injection,
the development of neurofibrillary degeneration was observed.
This Tau pathology progressed from the injection site to neighbor-
ing brain structures, suggestive of a diffusible and transmissible
propagating mechanism (Clavaguera et al., 2010). Very recently,
Frost et al. (2009) have shown using a cell-based system that extra-
cellular Tau aggregates are internalized inside cells and promote
the mis-folding and fibrillization of Tau. Internalization of pre-
formed Tau fibrils is facilitated by the use of a lipid-based protein
delivery system (BioPorter®) and is likely mediated by endocyto-
sis (Guo and Lee, 2011). The internalized preformed fibrils reduce
microtubule-stabilization suggesting a loss-of-function of normal
Tau in infected cells. Moreover, two recent studies showed that the
tau pathology could spread in vivo through neuronal circuitry and
trans-synaptic transmission (De Calignon et al., 2012; Liu et al.,
2012). Although those transgenic models are valuable to decipher
the molecular and cellular mechanisms of tau pathology spread-
ing, the mechanism of tau protein conversion, oligomerization,
secretion, trans-synaptic propagation remains elusive. There are
some evidences suggesting that Tau may be secreted and secretion
of Tau may differ depending on Tau isoform. Thus, Tau isoforms
with exon 2 encoding sequence are likely not secreted and this
exon 2 sequence is therefore suggested to repress Tau secretion
(Kim et al., 2010). A good example of such a dilemma is fibrob-
last growth factor 2 that is a secreted growth factor without any
signal peptide and that is also found in cell nucleus following
its interaction with its cognate receptors (Meunier et al., 2009).
Tau is likely secreted and is also located into the nucleus follow-
ing stress conditions (Sultan et al., 2011). Tau secretion, as for
Tau nuclear localization, may depend upon yet undefined condi-
tions and therefore, contributions of MVB-exosomes pathways or
autophagy-lysosomal pathways (Wang et al., 2009) remain com-
pletely open. Recent data strongly suggest that both pathways are
possibly interconnected (Sahu et al., 2011). With regards to Tau,
the degradation systems may bring insights for the potential rout-
ing of Tau to MVB-exosomes or autophagy-lysosome pathway. In
NFT or more generally in aggregates, Tau is found ubiquitinated,
thus suggesting that Tau may be processed by the proteasome
(David et al., 2002). Ubiquitin-independent degradation system,
such as caspase or calpain cleavage of Tau has also been described
(Berry et al., 2003; Delobel et al., 2005; Ding et al., 2006; Carrettiero
et al., 2009; Ferreira and Bigio, 2011). The autophagy-lysosomal
pathway contributes to the degradation of Tau via the chaperone-
mediated autophagy (CMA; Wang et al., 2009; for review see Wang
et al., 2010). The CMA is a lysosome-mediated degradation sys-
tem of cytosolic protein (for review see Arias and Cuervo, 2011).
This system implies the recognition of substrates by a complex
of chaperones and translocation of substrates inside lysosomes
for further degradation. The CMA malfunction has been con-
nected to the development of several neurodegenerative diseases
including Parkinson disease and AD (Arias and Cuervo, 2011).
Although speculative and purely hypothetic, through the use of
CMA, aggregates of proteins or even oligomers could reach the
lysosome and due to their low sensitivity to degradation (e.g.,
Tau aggregates), the fusion of lysosome with other vesicular struc-
tures such as MVB could finally lead to the release of aggregates
outside the cell and contribute to their propagation following
neuronal connections. Alternatively, proteins such as Tau would
normally be addressed to lysosome by the CMA system but a
defective lysosome could be the place where oligomers are gener-
ated and thereafter route to MVB/exosome pathway. More recently,
two consecutive papers described the secretion of Tau protein by
the exosome pathway (Saman et al., 2012; Simon et al., 2012). In
MC1 neuroblastoma cells overexpressing the four-repeat Tau iso-
form with no N-terminal insert, a C-terminal truncated form or
the full-length Tau protein was found co-purified with exosomes
as well as associated with the exosome fraction obtained from
human cerebrospinal fluid (Saman et al., 2012). Other Alzheimer
associated markers are found in exosome such as Fyn-tyrosine
kinase and Aβ (Segura et al., 2005; Rajendran et al., 2006). These
proteins were also found in exosomes secreted by MC1 neu-
roblastoma cells (Saman et al., 2012). Interestingly, while the
full-length Tau is recovered from COS cells overexpressing Tau,
in HEK stably expressing Tau protein, a fragment encompass-
ing Tau microtubule-binding repeat domains is principally found
(Simon et al., 2012). However, endogenous Tau was not detected
in exosomes derived from primary embryonic neuronal culture
cells (Faure et al., 2006). Exosomes-associated secretion of Tau is
only observed in overexpressing systems suggesting that the release
of Tau by the exosomes pathway may contribute to eliminate the
excess of intracellular Tau. Recent studies suggest that many trans-
missible pathogens such as PrP, α-synuclein, Huntingtin, Aβ are
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shuttle from a cell to another by secretion or tunneling nanotubes
(for review see Goedert et al., 2010), however the mechanism
of secretion or transmission and their regulation remain poorly
understood.
HOW TAU PATHOLOGY TRANSMISSION IS SELECTIVE IN SPORADIC
TAUOPATHIES?
Conceptually, what mechanism can we propose to explain the
prion-like spreading of Tau pathology affecting selective patterns
of neurodegeneration and skipping nearby “less vulnerable” neu-
ronal targets. That’s certainly a major fundamental question to
address. Why in the scheme of spatiotemporal spreading and prop-
agation of lesions in AD and other sporadic Tauopathies such
as Pick’s disease, progressive supranuclear palsy or corticobasal
degeneration only selective neuronal subpopulations are affected
(for review see Sergeant et al., 2008). As for instance, affected neu-
rons in AD essentially belong to the cholinergic system whereas
those degenerating in PSP are dopamine neurons (Murphy et al.,
2008). One possibility would be that selectivity of propagation
could follow neuronal circuitry through synaptic transmission.
This would be possible if exosomes were preferentially released at
the synaptic junction, as suggested by Smalheiser (2007). There
are emerging evidence that exosomes are produced and secreted
by neurons and that synaptic activity could enhance exosomes
secretion (Lachenal et al., 2011). However, the demonstration
derives from in vitro experiments using primary neuronal embry-
onic culture cells. Study of exosomes in tissue yet remains highly
challenging although recently it was shown that exosomes could
be detected in synaptic boutons at the Drosophila larval neuro-
muscular junction (Koles et al., 2012). Consequently, little if not
nothing is known about the neuronal localization, regulation of
release and their propensity of diffusion in vivo.
There are therefore other possibilities, such as the tunnel-
ing nanotubes (for review see Goedert et al., 2010). Tunneling
nanotubes are fine membrane channels that have recently been
described in mammalian cells for communication between cells
but also for cell-to-cell propagation of mis-folded PrPs (for review
see Gerdes et al., 2007; Gousset et al., 2009; Zhang, 2011). These
tunneling nanotubes could also propagate other transmissible
mis-folded proteins such as Aβ (Zhang, 2011) but the question
of selectivity of transmission remains open. However, it is note of
worthy that tunneling nanotubes is induced following oxidative
stress in rodent hippocampal neurons and astrocytes. Cell-to-
cell connection and communication of intracellular organelles
or Aβ could be trigged by cellular stress (Zhang, 2011). Follow-
ing this scheme, the stressed cell, such as a degenerating neuron,
would connect via tunneling nanotubes to closely surrounding
or connected neurons to deliver the pathogenic protein. However
hypothetic, tunneling nanotubes is an emerging mechanism of cell
communication under stress conditions that may or could con-
tribute to neurodegenerative diseases (Goedert et al., 2010; Zhang,
2011).
Coming back to exosomes and now considering that exo-
some release and secretion is controlled and localized to pre-
or post-synaptic locations then several hypotheses can be pos-
tulated. In both pre- and post-synaptic situations propagation
through exosomes would be closely dependent upon neuronal
connections, as far as the diffusion of exosomes is following a
paracrine or “juxtacrine” rule of diffusion (Mathivanan et al.,
2011). Thus, only interconnected neurons would disseminate
toxic species via exosomes. We can also hypothesize that exo-
somes originating from different type of neurons (e.g., cholinergic,
GABAergic, glutamatergic, dopaminergic. . .) may contain specific
membrane-associated biomarkers. Intercellular communication
mediated by exosomes may result from passive fusion of exo-
some membrane with the plasma membrane of the targeted cell
or may use a ligand receptor system. In line with the latter sys-
tem, the selectivity of intercellular communication could result
from specific interaction between ligand and receptor. There are
several examples that could illustrate a selectivity of propagation
of exosomes using this ligand receptor selectivity. For instance,
protocadherin is a cluster of 52 cadherin-like genes with a singu-
lar organization. The amino-terminal region of protocadherins is
encoded by three sets of separate exons arranged in three clusters
(alpha, beta, and gamma). N-terminal encoding exons are spliced
with one of three carboxy-terminal encoding exons. Alternative
splicing generates an extraordinary diversity of protocadherin
isoforms suggested to confer selective and specific intermolecu-
lar membrane-associated protein interactions (Wu and Maniatis,
2000; Wang et al., 2002). The second example is DSCAM, the
Drosophila homolog of human Down syndrome cell adhesion
molecule that belongs to the axonal guidance receptor family.
Alternative splicing of DSCAM can generate as many as 38016
mRNA isoforms and therefore lead to expression of huge pro-
tein diversity (Schmucker et al., 2000). More interestingly, one
DSCAM protein isoform binds exactly to the same isoform but
not a slightly different one, making the binding of DSCAM iso-
forms very stringent (Wojtowicz et al., 2004). As for DSCAM, the
selectivity of transmission pattern could be mediated following
an axonal guidance-like system. In a very simplified view, axonal
guidance is driven by equilibrium between attractive and repul-
sive signals through specific signaling pathways, allowing axonal
growth and connection to its specific neuronal target (for review
see Bashaw and Klein, 2010). Thus exosome release from one type
of cell will be attracted by its target cell and repulsed by sur-
rounding cells. Altogether, examples provided could contribute to
neuronal communication and propagation of mis-folded proteins
along specific identified neuronal circuitries. Although all these
hypotheses could be envisioned a better knowledge of the metab-
olism of exosomes in vitro and in vivo is necessary to address this
problematic.
CONCLUSION
Among pathophysiological mechanisms of neurodegenerative dis-
eases leading to intra or extracellular protein aggregates, a consen-
sual mechanism support a prion-like propagation of mis-folded
proteins. However, when this mechanism implies the propaga-
tion from cell-to-cell, shuttling pathways incriminated remains
poorly understood (see Figures 4 and 5 for potential hypothe-
sis). A growing body of evidence suggests that the endocytic –
multivesicular endosome and exosome pathways may contribute
to this process and to the development of several neurodegen-
erative diseases. Much is known about the routing of proteins
through those recycling or degradative pathway but much less is
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FIGURE 4 |APP and its metabolites are present in multivesicular bodies
and exosomes. APP and APP-CTFs are internalized and directed into the
internal vesicles of multivesicular bodies (MVB). At this point APP and its
metabolites can either be degraded after the fusion of MVB with lysosomes
or can be released in the extracellular space in association with exosomes
consecutively to the fusion of MVB with the plasma membrane.
known about the contribution of those systems to the develop-
ment of neurodegenerative diseases. However, this MVB – exo-
some system can be diverted from its physiological function as
for instance to produce human immunodeficiency viral particles
(Nguyen et al., 2003; for review see Gould et al., 2003). Following
this hypothesis, the autophagy-lysosome and/or MVB – exosome
pathways could also be diverted to deliver and propagate toxic
oligomers or aggregates in neurodegenerative diseases such as AD.
Blocking the diffusion of those toxic and mis-folded species by
this secretory pathway could also represent a potential therapeutic
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FIGURE 5 | Hypothesis of pathological tau spreading. How can
pathological tau species spreads through trans-synaptic connections? A
non-exhaustive representation of several hypotheses are given. (1)
Pathological species can be endocytosed recycled, amplified, transport, and
secreted (2) Endocytosed species can follow the endosome lysosome routing
and either be addressed to lysosomes or to multivesicular endosomes/bodies
(3) Pathological tau species that are produced in the cell soma are included
into multivesicular bodies by inward budding of the late endosome membrane
(4) Pathological tau species can be included into large autophagic vesicles by
macroautophagy and further fused with multivesicular bodies (5) pathological
tau species can be release by fusion of multivesicular bodies with the plasma
membrane at the synaptic junction and capture by the connected dendrite.
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approach of neurodegenerative diseases such as Amyloidopathies,
Tauopathies, Synucleinopathies, or more largely Foldopathies all
of which are likely sharing a “prion-like” propagation of toxic
mis-folded proteins.
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